Track global drug development
A database collating 50,251+14 drugs across 218,207+412 trials.
-
We source from
- 218,207
- registered trials
- 356,862
- press releases
- 38,616
- organisations
-
Every fact is cited
“the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint” Missed primary endpoint ionis.com ↗ -
Updated hourly
Updated hourly across 100s of sources
-
Follow what you need
- modalityAntibody+indicationOncology
- targetGLP-1+phase3 and later
- indicationCancer+regionEU
- sponsorNovartis